Status:

ACTIVE_NOT_RECRUITING

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Lead Sponsor:

Synthekine

Conditions:

Systemic Lupus Erythematosus

Lupus Nephritis

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.

Detailed Description

SYNCAR-001 + STK-009 is a 2-component human orthogonal (ho) IL-2 receptor-ligand cell therapy consisting of (1) SYNCAR-001, a CD19-directed chimeric antigen receptor T cell (CAR-T) co-expressing an en...

Eligibility Criteria

Inclusion

  • General
  • Age ≥18 years at screening.
  • SLE
  • Clinical diagnosis of SLE according to the 2019 European League Rheumatism EULAR/ACR classification criteria.
  • Subject must be positive for at least one of the following at screening: Anti-dsDNA (above the upper limit of normal \[ULN\]); or anti-Sm (above the ULN); or anti-Chromatin (above the ULN).
  • Subjects with active, severe, non-renal SLE or subjects with active proliferative LN
  • SSc
  • Classified as SSc according to the ACR/EULAR classification criteria.
  • Diffuse cutaneous SSc (dcSSc) or SSc-associated ILD (SSc-ILD; significant or progressive).
  • General

Exclusion

  • History of or active central nervous system manifestations of autoimmune disease.
  • Prior treatment with anti-CD19 adoptive T cell therapy, or any prior gene therapy product (e.g., CAR T cell therapy).
  • SLE

Key Trial Info

Start Date :

April 29 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2041

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT06544330

Start Date

April 29 2025

End Date

April 1 2041

Last Update

November 4 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

HonorHealth Research Institute

Scottsdale, Arizona, United States, 85258

2

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

3

Feinstein Institutes for Medical Research

Manhasset, New York, United States, 11030

4

The Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44195

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease | DecenTrialz